Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:43:02 EDT Fri 04 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:EPRX - EUPRAXIA PHARMACEUTICALS INC. J - https://www.eupraxiapharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EPRX - T  2.111.36·11.700.111.64+1.2812.4237.12,5921,35510.35  11.64  10.2412.86  7.1516:00:00Aug 1315 min RT 2¢
TSX - T2.111.36·11.700.111.64+1.2812.4102.71,11868510.35  11.64  10.2612.86  7.1516:00:0015 min
NEO ATS - U 11.58+1.2211.835.238616110.29  11.58  10.2715:58:5115 min
Alpha - A 11.60+1.2412.01.011711.10  11.60  11.1015:59:3015 min
Omega - O 11.58+1.2211.81.415910.24  11.58  10.2415:59:3015 min
CSE ATS - P 11.61+1.2512.13.6411111.37  11.61  11.3015:59:2415 min
CXC - X 11.60+1.2412.060.066320710.41  11.61  10.4115:59:5915 min
CX2 - H 11.59+1.2311.913.815011710.28  11.595  10.2515:59:3115 min
CXD - D 11.61+1.2512.17.1757710.40  11.61  10.4015:59:4415 min
MatchNOW - M 10.365.66148    15 min
Lynx - Y 11.62+1.2612.26.6713210.42  11.62  10.4115:59:5915 min
CS2 - S 10.360.0611    Aug 2415 min

Recent Trades - Last 10 of 1355
Time ETExPriceChangeVolumeBuyerSellerMarkers
16:11:02X11.641.28180 National Bank80 National BankZW
16:11:02X11.641.28180 National Bank80 National BankZW
16:00:00T11.641.2810053 Morgan Stanley80 National BankKQ
16:00:00T11.641.2810053 Morgan Stanley39 Merrill LynchKQ
15:59:59X11.601.2410079 CIBC14 Virtu ITGK
15:59:59X11.601.2410079 CIBC14 Virtu ITGK
15:59:59Y11.621.2610079 CIBC79 CIBCK
15:59:59T11.621.2610079 CIBC79 CIBCK
15:59:59T11.631.2720079 CIBC79 CIBCK
15:59:56T11.621.2620079 CIBC79 CIBCK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2026-08-13 16:59C:EPRX9.32News ReleaseEupraxia talks improved EoE symptoms in phase 1/2 trial
2026-08-11 21:07C:EPRX9.35SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2026-08-11 18:59C:EPRX9.35SEDAR Interim MD & ASEDAR Interim MD & A
2026-08-11 18:58C:EPRX9.35SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2026-08-11 17:21C:EPRX9.35News ReleaseEupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-08-04 12:55C:EPRX9.12SEDAR Preliminary Short Form ProspectusSEDAR Preliminary Short Form Prospectus
2026-08-04 11:16C:EPRXSEDAR Final Short Form ProspectusSEDAR Final Short Form Prospectus
2026-07-13 19:31C:EPRX9.09News ReleaseEupraxia Pharmaceuticals appoints EVPs
2026-07-07 18:57C:EPRX9.48News ReleaseEupraxia Pharmaceuticals appoints three directors
2026-06-19 16:09C:EPRX9.17News ReleaseEupraxia shareholders approve all matters at AGM
2026-05-28 08:00C:EPRX9.92News ReleaseEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2026-05-12 17:00C:EPRX10.51News ReleaseEupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-12 10:10C:EPRX10.51SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2026-05-12 10:10C:EPRX10.51SEDAR Interim MD & ASEDAR Interim MD & A
2026-05-06 07:00C:EPRX9.88News ReleaseEupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
2026-05-05 07:00C:EPRX10.08News ReleaseEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
2026-05-01 20:02C:EPRX10.75News ReleaseEupraxia appoints Tambiah as CMO
2026-04-22 07:00C:EPRX9.63News ReleaseEupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
2026-04-21 07:00C:EPRX9.90News ReleaseEupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
2026-04-20 12:29C:EPRX9.74News ReleaseCanadian Investment Regulatory Organization Trading Halt - EPRX.WT.A